IndustryCompany release

Exelixis lifts Q3 revenue to $658.7m as zanzalintinib colorectal filing awaits FDA decision

🇺🇸 Exelixis, Inc. (EXEL) · Thu 29 Oct 2026

The company reported higher third-quarter sales, held its 2026 revenue guidance and lowered its tax-rate outlook, with a March 2027 FDA action date set for zanzalintinib.

Exelixis reported total revenues of $658.7 million for the third quarter of 2026, up from $597.8 million in the same period a year earlier. The company announced the figures on 29 October 2026.

U.S. net product revenues from cabozantinib, the active ingredient in Cabometyx, reached $604.9 million in the quarter. Exelixis attributed the revenue increase to growth in Cabometyx.

The company left its 2026 revenue guidance unchanged. It did, however, lower its expected effective tax rate for the year to a range of 16% to 18%.

On the pipeline, the US Food and Drug Administration is reviewing a new drug application for zanzalintinib in combination with atezolizumab. The proposed indication is previously treated metastatic colorectal cancer, and the agency has set a PDUFA target action date of 3 March 2027.

For context, a PDUFA date is the goal date by which the FDA aims to complete its review of an application. It is a target and not a guarantee of approval.

What it means for your team

  • Regulatory teams tracking oncology filings can note the 3 March 2027 PDUFA date for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.
  • Market-access teams should watch for a possible new treatment option in a later-line colorectal setting, although the application is still under review.
  • Unchanged 2026 revenue guidance suggests no change in the company's full-year commercial outlook for its marketed cabozantinib products, based on the information available.

Company's press release (SEC filing): Exelixis, Inc. ↗

Article written by VigiEye from the official source (Exelixis, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →